UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended:September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-06064 ALEXANDERS INC (Exact name of registrant as specified in its charter) Delaware 51-0100517 | --- | --- | |----------- ...

Core Insights - ALX Oncology announced that results from a Phase 1b/2 trial of evorpacept in combination with zanidatamab for HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium in December 2024 [1][2] Group 1: Clinical Trial Details - The Phase 1b/2 clinical trial is an open-label, multicenter study (NCT05027139) assessing evorpacept and zanidatamab as a treatment for HER2-expressing breast cancer and other cancers [2] - The presentation will include the title "Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study" with Abstract Number SESS-2007 [2] - The presentation is scheduled for December 12, 2024, from 7:00 a.m. to 8:30 a.m. CST at the Henry B. Gonzalez Convention Center, San Antonio, Texas [2] Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that enhance the immune system to treat cancer and improve patient survival [3] - The lead therapeutic candidate, evorpacept, is positioned as a potential cornerstone therapy for future immuno-oncology treatments and is being evaluated in multiple ongoing clinical trials across various cancer indications [3]

PARAMUS, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 4, 2024, before the New York Stock Exchange opens. Vornado Realty Trust (NYSE: VNO), the manager which conducts Alexander’s operations, announced it will host its quarterly earnings conference call and an audio ...

Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESOctober 11, 2024 2:12 PM EDT | Source: ALX Resources Corp.Vancouver, British Columbia--(Newsfile Corp. - October 11, 2024) - Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3)  ("Greenridge" or the "Company") and ALX Resources Corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6 ...

Core Viewpoint - Alexander's, Inc. has successfully completed a $400 million refinancing of the office condominium portion of 731 Lexington Avenue, significantly reducing its interest rate and extending the loan maturity [1] Group 1: Loan Details - The new loan is an interest-only loan with a fixed rate of 5.045% and matures in October 2028 [1] - The refinancing replaces a prior $490 million loan that had an interest rate tied to the Prime rate, currently at 8.00%, and was set to mature in October 2024 [1] - The new loan allows for prepayment at Alexander's option without penalty starting in October 2026 [1] Group 2: Company Overview - Alexander's, Inc. is a real estate investment trust (REIT) that owns five properties in New York City [1]

Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 18th:Alexander's (ALX) : This real estate investment trust which is engaged in leasing, managing, developing and redeveloping properties, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 15.5% over the last 60 days.This Zacks Rank #1 (Strong Buy) company has a dividend yield of 7.4%, compared with the industry average of 4.2%.J. Sainsbury (JSAIY) : This leading ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:SharkNinja, Inc. (SN) : This is a diversified, product design and technology company which creates lifestyle solutions through products for consumers, has seen the Zacks Consensus Estimate for its current year earnings increasing 10.7% over the last 60 days.Alexander's (ALX) : This real estate investment trust which is engaged in leasing, managing, developing and redeveloping properties, has seen the Zacks Consensus Estimate for its cur ...

Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 13:BancFirst Corporation (BANF) : This bank holding company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% the last 60 days.This Zacks Rank #1 company has a dividend yield of 1.6%, compared with the industry average of 0.7%.Alexander's, Inc. (ALX) : This real estate investment trust has witnessed the Zacks Consensus Estimate for its current year earnings ...

Smederevac/iStock via Getty ImagesALX Oncology Holdings Inc. (NASDAQ:ALXO) develops immuno-oncology treatments to improve the immune response against cancer. The company’s leading product candidate is Evorpacept [ALX148], a first-in-class CD47 inhibitor that blocks cancer cells' “don’t eat me” signal. Unlike standard CD47 inhibitors, Evorpacept has an inactive Fc domain that reduces side effects. ALXO’s pipeline explores diverse combinations of Evorpacept with chemotherapy, targeted agents, and checkpoi ...

Core Viewpoint - Greenridge Exploration Inc. has signed a non-binding letter of intent to acquire ALX Resources Corp., aiming to create a leading Canadian uranium exploration company with a diversified portfolio of strategic metals projects [4][5]. Group 1: Proposed Transaction Details - The acquisition will involve Greenridge acquiring all outstanding common shares of ALX, resulting in a combined entity with interests in 28 projects covering approximately 493,000 hectares [4][5]. - The transaction is characterized as an arm's length deal, enhancing the capital markets profile with an expected market capitalization of approximately C$35 million [5]. - ALX shareholders will receive a significant premium of 130% based on the 20-day VWAP of ALX shares, with an exchange ratio of 0.045 Greenridge shares for each ALX share [8][19]. Group 2: Strategic Rationale - The merger will consolidate one of the largest uranium property portfolios in the Athabasca Basin, including significant projects like Black Lake and Gibbons Creek, which have shown promising uranium mineralization [5][9]. - The combined entity will also have exposure to lithium, nickel, copper, and gold properties, diversifying its mineral portfolio [5][14]. - The transaction is expected to yield material cost savings through the consolidation of corporate operations and investor relations activities [5]. Group 3: Management and Governance - Post-transaction, the Board of Directors will include members from both companies, with Warren Stanyer from ALX joining as President and Director of Greenridge [18]. - Russell Starr will continue as CEO of the combined entity, ensuring continuity in leadership [18]. Group 4: Project Portfolio - ALX's uranium project portfolio includes key properties such as Hook-Carter, Black Lake, and Gibbons Creek, which are located in prime uranium exploration districts [9][28]. - The combined portfolio will enhance exploration capabilities and discovery potential across various strategic minerals [5][9].